NCT06550102 Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
| NCT ID | NCT06550102 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Children's Hospital, Zurich |
| Condition | Hematological Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-01-04 |
| Primary Completion | 2031-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-01-04 with a primary completion date of 2031-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.
Eligibility Criteria
Inclusion Criteria: * Pediatric and adult patients below the age of 40 years * Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma * Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research * Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research. Exclusion Criteria: * Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research
Contact & Investigator
Jean-Pierre Bourquin, MD, PhD
STUDY CHAIR
University Children's Hospital Zurich
Frequently Asked Questions
Who can join the NCT06550102 clinical trial?
This trial is open to participants of all sexes, up to 40 Years, studying Hematological Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06550102 currently recruiting?
Yes, NCT06550102 is actively recruiting participants. Contact the research team at Jean-Pierre.Bourquin@kispi.uzh.ch for enrollment information.
Where is the NCT06550102 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT06550102 clinical trial?
NCT06550102 is sponsored by University Children's Hospital, Zurich. The principal investigator is Jean-Pierre Bourquin, MD, PhD at University Children's Hospital Zurich. The trial plans to enroll 1,000 participants.